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OBJECTIVES The aim of this study was to evaluate the effect of variable dose and release kinetics of
paclitaxel on neointimal hyperplasia.
BACKGROUND Conventional paclitaxel-eluting stents use a durable polymer coating as a vehicle for drug
delivery. The Conor stent (Conor Medsystems, Menlo Park, California) with intra-strut wells
and erodable polymer is specifically designed for drug delivery with programmable pharma-
cokinetics.
METHODS Two hundred and forty-four patients with single vessel disease received either a bare metal
Conor stent (n  53) or one of six different release formulations that varied in dose (10 or 30
g) and elution release kinetics (first order, zero order), direction (abluminal, luminal), and
duration (5, 10, and 30 days). End points at six months (bare stent group) and at four months
(eluting stent groups) were angiographic late loss and neointimal tissue volume by intravas-
cular ultrasound and the rate of major adverse cardiac events (MACE).
RESULTS The lowest in-stent late loss (0.38 mm, p 0.01, and 0.30 mm, p 0.01) and volume
obstruction (8%, p 0.01, and 5%, p 0.01) were observed with the 10-g and 30-g doses
in the 30-day release groups respectively, whereas the highest in-stent late loss (0.88 mm),
volume obstruction (26%), and restenosis rate (11.6%) were observed in the bare stent group.
The overall MACE rate of the eluting stent group was 8.6%: death 0.5%, myocardial
infarction 2.7%, and target lesion revascularization (TLR) 5.3%. Sub-acute thrombosis was
0.5%. The TLR rates in the two 30-day release groups were 0% and 3.4%.
CONCLUSIONS This novel eluting stent platform, using an erodable polymer with complete elution of low
doses of paclitaxel, is safe. The inhibition of the in-stent neointimal hyperplasia was best in
the long release groups. (J Am Coll Cardiol 2005;46:253–60) © 2005 by the American

















erug-eluting stents (DES) have recently been introduced to
linical practice and have revolutionized the treatment of
oronary artery disease. Several randomized clinical studies
ave demonstrated significant reduction of restenosis and
evascularization rates, into the single digits, compared with
are stents (1–4).
Each DES comprises three components: the stent
latform, the active pharmacologic compound, and a
rug carrier vehicle, usually a polymer, that controls drug
lution. Conventional research for development of new
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Manuscript received November 30, 2004; revised manuscript received March 17,
005, accepted March 29, 2005.nd more effective DES has focused on the use of new
rugs and advanced biocompatible polymers coated on
tent struts. This approach has limitations, including
imited control of kinetic profiles and drug-loading
apacity.
A novel metallic stent has been engineered specifically
s a coronary drug delivery system. It is designed to
ermit precise and programmable control over spatial and
emporal release profiles and to enhance the drug-loading
apacity (5).
The present study evaluates this new stent platform
ithout drug and with six different pharmacokinetic release
ormulations of paclitaxel. These formulations have previ-
usly been investigated for their safety and efficacy in animal
odels (6). The objective of the Paclitaxel In-Stent Con-
rolled Elution Study (PISCES) trial is to compare the
afety and performance of different doses and release rates
rom the Conor paclitaxel-eluting stent for reducing clinical
vents and angiographic late loss at four months when used
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tudy design. The PISCES trial was preceded by the
egistry phase of the bare Conor stent so as to establish
afety and for use as a historical control. Angiographic and
ntravascular ultrasound (IVUS) follow-up was planned at
ix months in the bare stent registry. Fifty-three patients
ere included in this cohort.
The PISCES trial was a prospective, multi-center, se-
uentially enrolled, non-randomized, open-label trial in
hich the patient data collected from six release formula-
ions were compared with one another and to the historical
are stent cohort.
One hundred and ninety-one subjects from the ten
articipating sites were enrolled in the PISCES trial and
eceived a paclitaxel-eluting stent with one of the six release
ormulations. At least one study stent was implanted in each
ubject. When additional stents were required for treatment
f edge dissection, stents from the same formulation type
ere used.
Clinical follow-up was conducted at one and four months
fter the index procedure. Quantitative angiography and
VUS were performed at four months. Provisional angio-
raphic and IVUS follow-up is planned at 12 months in the
ose treatment groups showing efficacy.
nd points. The safety end point of the study is a com-
osite of major adverse cardiac events (MACE), defined as
eath, Q-wave or non–Q-wave myocardial infarction (MI),
nd target lesion revascularization (TLR; coronary artery
ypass grafting or percutaneous coronary intervention) at
our months. All deaths were considered cardiac unless they
ere unequivocally documented to be non-cardiac. Myocar-
ial infarction was diagnosed by a rise in the creatine kinase
evel to more than twice the upper normal limit with an
ncreased creatine kinase-MB accompanied by new abnor-
al Q-waves in the surface electrocardiogram (Q-wave MI)
r not (non–Q-wave MI). Target lesion revascularization
as defined as revascularization of the stented and the
eri-stent segments (5 mm proximal and distal). Target
essel revascularization (TVR) was defined as revasculariza-
ion due to narrowing (50% diameter stenosis) of any
ortion of the target vessel outside the peri-stent segment,
Abbreviations and Acronyms
DES  drug-eluting stent(s)
IVUS  intravascular ultrasound
LV  lumen volume
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal luminal diameter
PISCES  Paclitaxel In-Stent Controlled Elution Study
QCA  quantitative coronary angiography
SV  stroke volume
TLR  target lesion revascularization
TVR  target vessel revascularizationut was not included as an event in the MACE rate. Both bLR and TVR are reported as actual rates without adjudi-
ation for clinical indication.
The efficacy end points included the in-stent and peri-
tent angiographic late loss and binary restenosis rate as well
s percent volume obstruction of the stent and neointimal
yperplasia of the stented and peri-stent segments, as
etermined by quantitative IVUS.
atient selection. Subjects were eligible for the study if
hey were 18 to 80 years of age, had single de novo lesions
ith a reference diameter of 2.5 to 3.5 mm and a lesion
ength that could be covered by a single 17-mm stent, and
f they had stable or unstable angina pectoris or documented
ilent ischemia.
Subjects were excluded from the study if they had an
cute MI 72 h before the procedure, an ejection fraction
30%, stroke/gastro-intestinal bleeding within six months,
evere hepatic disease or renal insufficiency with a serum
reatinine level 2.5 mg/dl, or known intolerance or con-
raindication to aspirin and/or clopidogrel. Further angio-
lasty exclusion criteria included total occlusions (Throm-
olysis In Myocardial Infarction flow grade 0), bifurcational
adjacent branch 2 mm) and ostial lesions, left main
isease, and tortuous target vessel. Written informed con-
ent was obtained from all patients.
The inclusion and exclusion criteria for both the bare
etal registry phase and the PISCES trial were identical.
tudy device. Figure 1 shows the balloon-expandable,
16L stainless steel Conor stent. The unique design features
nclude struts with holes along their length, linked to
exible sinusoidal bridges by specially contoured features
alled ductile hinges. Unlike conventional stents consisting
f repeating units wherein the entire structure is deformed
igure 1. Single cell of the Conor stent showing the intra-strut wells (a)
lled with erodable polymer (b). The ductile hinge allows full deployment
f the stent without deformation of the wells containing the drug. The
elease of the drug (c) can be either uni-directional toward the vessel wall
abluminal) or bidirectional toward the lumen of the vessel (luminal) and
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July 19, 2005:253–60 The PISCES Trialhat deformation is confined to the 10% of the stent
omprising the ductile hinges, rendering the struts as passive
lements. This allows the struts to be cored with holes or
eservoirs for drug delivery with no effect on the strength or
rush resistance of the struts. The holes can be inlaid with
olymer/drug that will not deform or separate from the
tent during stent expansion, and bench testing shows no
xtrusion of polymer (5). The strut thickness is 127 m
range 122 to 132 m).
Each stent is loaded with paclitaxel within a bioresorbable
olylactide-co-glycolide matrix. An automated micro-jet
ystem is used to evenly load the polymer/drug combination
y depositing individual drops within each hole. The
mount of polymer and the surface area of polymer in
ontact with the vessel wall are minimized, offering a lower
hance of polymer-related effects. The drug is released by
rosion of the polymer and by diffusion. Predetermined
elease kinetics can be “programmed” by varying the method
nd concentration of drug deposition in the holes. At the
nd of the release period, neither polymer nor drug is
etained on the stent.
ose and kinetic release profiles. The drug under evalu-
tion in the PISCES study was paclitaxel. The Conor stent
s designed to deliver a similar dose density (measured in
g/mm2 of vessel surface area) to all vessels treated; stents
omprise varying numbers of stent cells. As the stents
ncrease in diameter, more stent cells are used to complete
he structure. In this way, the total contained dose on the
tent will increase in proportion to the vessel diameter,
hereby maintaining approximately a consistent dose per
nit of vessel surface area (6). The PISCES trial evaluated
igure 2. The six kinetic elution profiles, with their respective duration of
lution (days, x axis), kinetic release (zero or first order; see slope of curve),
umulative dose (g, y axis), and direction of elution (*bidirectional release,
*abluminal (mural) release only). PTX  paclitaxel.
able 1. Release Formulations
D1 D2
ose (g/17-mm stent) 10 10
uration of elution (days) 5 10




ey 10/5/b 10/10/bne of six different release formulations that varied in dose
10 or 30 g) and elution release kinetics (first order, zero
rder), direction (abluminal, luminal), and duration (5, 10,
nd 30 days). The release profiles for the formulations are
hown in Figure 2 and Table 1.
ntiplatelet therapy. Double antiplatelet therapy (aspirin
80 mg daily and clopidogrel 75 mg daily) was prescribed
or at least six months after procedure. A loading dose of
00 mg clopidogrel was given before the procedure.
uantitative coronary angiography evaluation. Quanti-
ative coronary angiography (QCA) was performed by
eans of the CAAS II analysis system (Pie Medical BV,
aastricht, the Netherlands). In each patient, the following
egments were analyzed:
. Stented segment: defined by the radiopacity of the Conor
stent.
. Peri-stent segments: defined by a length of 5 mm
proximal and distal to the stent edge.
The following QCA parameters were computed:
omputer-defined minimal luminal diameter (MLD), ref-
rence diameter obtained by an interpolated method, and
ercentage diameter stenosis. Binary restenosis was defined
n every segment as diameter stenosis 50% at follow-up.
ate loss was defined as the difference between MLD after
rocedure and MLD at follow-up.
uantitative IVUS. Post-procedure and follow-up stented
essel segments were examined with mechanical IVUS
Cardio Vascular Imaging System, CVIS, Sunnyvale, Cal-
fornia) with automated pullback at 0.5 mm/s. A coronary
egment beginning 5 mm distal to and extending 5 mm
roximal to the stented segment was also examined. A
omputer-based contour detection program was used for
utomated three-dimensional reconstruction of the stented
nd adjacent segments. The lumen, stent boundaries, and
xternal elastic membrane (vessel boundaries) were detected
ith a minimum cost algorithm. The stent volume (SV) and
umen volume (LV) were calculated according to Simpson’s
ule. The intra-stent neointimal volume was calculated as
SV-LV.” The percentage obstruction of the SV was calcu-
ated as intra-stent neointimal volume/SV  100. Feasibil-
ty, reproducibility, and inter- and intra-observer variability
f this system have been validated in vitro and in vivo (7,8).
he IVUS data of the proximal and distal peri-stent
egments are expressed in mean area (vessel and lumen area)
nstead of volume, because the analyzable lengths of these
egments were variable, owing to anatomical (side branch)
D3 D4 D5 D6
10 30 10 30
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The PISCES Trial July 19, 2005:253–60nd/or technical limitations. The “plaque” behind the stent
truts was also expressed in mean area.
tatistical analysis. Continuous parameters were pre-
ented as mean values and standard deviations, and discon-
inuous parameters as percentages. For lesion characteristics
nd procedural outcomes, the following tests were applied
o calculate the differences among the seven groups (one
are stent and six paclitaxel-eluting stent groups): F test
rom an analysis of variance (ANOVA), two-sample t test,
ikelihood ratio chi-square test, Fisher exact test, and
ochran-Mantel-Haenszel test. Overall QCA and IVUS
arameters were compared using general linear models (i.e.,
ne-way ANOVA) for unbalanced data. As per protocol,
he Student t test was performed between each release
ormulation and the bare stent group when ANOVA was
ositive, and, hence, no correction for multiple comparisons
as performed. The statistical significance of all tests was
efined at the p 0.05 level.
ESULTS
aseline characteristics and acute procedural out-
ome. Two hundred and forty-four patients (53 in the bare
tent group and 191 in the six paclitaxel-eluting stent
roups) were enrolled. The baseline patient characteristics
nd the procedural outcomes are presented in Tables 2 and
. A significant difference among the seven groups was only
ound in the mean age, which varied between 56.7  7.6
ears and 62.6  8.5 years, and in the history of smoking,
hich varied between 50.9% and 89.7%. Direct stenting was
erformed in 54% of the patients, and a total of 272 stents
1.1 stent per patient) were implanted. In six patients (bare
 3; eluting stent n  3), failure to cross the lesion
esulted in inability to implant the investigational device.
hese patients were not followed past the primary 30-day
afety end point. There were no MACE in these patients at
able 2. Baseline Patient Characteristics
Total Population
n  244
ge in yrs (mean  SD) 59.2  9.2
ender (% male) 70.5% (172/244)
istory of smoking 70.5% (172/244)
iabetes mellitus 18.0% (44/244)
ypertension 51.2% (125/244)
yslipidemia 66.8% (163/244)
rior MI 39.8% (97/244)
rior CABG 4.1% (10/244)
Prior PCI 13.5% (33/244)






Prior angioplasty and/or prior stent implantation.
CABG  coronary artery bypass graft; MI  myocardial infarction; PCI 
ercutaneous coronary intervention.0 days. The remaining 50 patients in the bare stent group nd 187 in the eluting stent group received the investiga-
ional devices and completed clinical follow-up (Table 4).
ACE. The clinical events are presented in Table 4. The
owest cumulative MACE and TLR rates were observed in
roups D5 (2.6% and 0%, respectively) and D6 (3.4% and
.4%, respectively). One patient in group D5 was readmit-
ed to the catheterization laboratory on the day of the
rocedure for an unrecognized dissection of the main stem,
nderwent bail-out stenting of the main stem, the left
ircumflex artery, the left anterior descending artery (target
essel), and sustained a major MI (CPK 6,634 U/l), dying
our days later resultant to cardiac rupture. One patient in
6 interrupted his aspirin and clopidogrel treatment three
ays after stent implantation and presented with subacute
cclusion and MI six days after the index procedure. At
ngiographic follow-up, 22 days after stent implantation,
he stented vessel was occluded. Attempt at percutaneous
evascularization was unsuccessful. As such, this patient was
ot included in the four-month angiographic follow-up
nalysis.
erial QCA analyses. Table 5 shows the serial QCA
nalyses. Each QCA parameter is the average of multiple
ngiographic views. Angiographic follow-up was available
n 93% of the patients. Groups D5 and D6 show the lowest
n-stent late loss, which is reduced approximately by 57%
nd 66%, respectively, when compared with the loss in the
are stent group. In D5 and D6, there were no cases of edge
estenosis. The overall restenosis rates in the stented and
eri-stent segments in D5 and D6 are 0% and 3.8%,
espectively, compared with 14% in the bare stent.
VUS. Follow-up IVUS was available in 85% of the pa-
ients. The lowest percent volume obstruction was observed
n groups D5 and D6 and was reduced by 69% and 81%,








VD (mm) 2.74  0.43
esion length (mm) 10.3  3.7




atients receiving treatment device 97.1% (237/244)
echnical success* 95.1% (232/244)
rocedural success† 93.0% (227/244)
inal diameter stenosis (%) 13  6
nable to cross lesion 2.5% (6/244)
evice malfunctions 2.0% (5/244)
Technical success is defined as the ability of the stent system to dilate the lesion with
20% residual stenosis (visual assessment) in the absence of a device-related failure or
omplications. †Procedural success is defined as technical success in the absence of any
n-hospital major adverse cardiac events (MACE).ACC  American College of Cardiology; LAD  left arterior descending; LCX
left circumflex; RCA  right coronary atery; RVD  reference vessel diameter.
Table 4. Clinical Events and MACE
Event Event Type
D0 Bare Stent D1 10/5/b* D2 10/10/b* D3 10/10/m* D4 30/10/b* D5 10/30/m* D6 30/30/m*
n  50 n  30 n  29 n  30 n  30 n  39 n  29
Duration of follow-up
(months)
6 4 4 4 4 4 4
Death — 0 0 0 0 0 1 0
MI Q-MI 0 1 0 0 1 1 1
Non–Q-MI 1 1 1 0 0 0 0
Death or MI 1 2 1 0 1 1 1
Revascularization TLR 3 5 4 2 1 0 1
TVR 1 0 0 1 0 2* 1
TVR-CABG 0 0 1 0 0 0 0
Any MACE 4 (8.0%) 5 (16.7%) 5 (17.2%) 2 (6.7%) 2 (6.7%) 1 (2.6%) 1 (3.4%)
*See Table 1 (release formulations): dose/duration/direction.
CABG  coronary artery bypass graft surgery; MACE  major adverse cardiac events and is a composite of death, myocardial infarction (MI), target lesion revascularization (TVR) (clinically justified or not), or emergent CABG;
TVR  target vessel revascularization and is not included as an event in the MACE rate; QM  Q-wave MI.














n  26 ANOVA
In stent
MLD post (mm) 2.66  0.37 2.60  0.31 2.57  0.33 2.70  0.38 2.49  0.33 2.68  0.36 2.52  0.35 0.11
MLD follow-up (mm) 1.79  0.44 1.87  0.52 1.90  0.63 2.02  0.51 2.02  0.49† 2.30  0.32‡ 2.26  0.47‡ 0.0001
Late loss (mm) 0.88  0.41 0.72  0.39 0.70  0.56 0.67  0.52 0.48  0.47‡ 0.38  0.34‡ 0.30  0.35‡ 0.0001
Restenosis rate % 11.6 10.3 10.7 3.6 6.9 0.0 3.8 0.38
Proximal stent edge
MLD post (mm) 2.77  0.49 2.66  0.53 2.63  0.53 2.85  0.44 2.55  0.50 2.69  0.53 2.60  0.45 0.21
MLD follow-up (mm) 2.23  0.5 2.38  0.52 2.32  0.68 2.51  0.39 2.38  0.49 2.47  0.52 2.48  0.54 0.28
Late loss (mm) 0.47  0.39 0.27  0.48 0.32  0.54 0.30  0.33 0.17  0.32‡ 0.23  0.39‡ 0.13  0.33‡ 0.01
Restenosis rate % 2.3 0.0 3.6 0.0 0.0 0.0 0.0 0.61
Distal stent edge
MLD post (mm) 2.38  0.45 2.32  0.41 2.30  0.50 2.32  0.51 2.14  0.54 2.37  0.42 2.27  0.48 0.46
MLD follow-up (mm) 2.17  0.45 2.15  0.34 2.21  0.52 2.09  0.52 2.03  0.47 2.30  0.38 2.23  0.39 0.27
Late loss (mm) 0.23  0.39 0.15  0.31 0.11  0.36 0.22  0.52 0.13  0.30 0.08  0.29 0.09  0.34 0.47
Restenosis rate % 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.58
Stent and peri-stent segments
Restenosis rate % 14 10.3 14.3 3.6 10.3 0.0 3.8 0.39
*See Table 1 (release formulations): dose/duration/direction; †p 0.05 compared with the bare stent group; ‡p 0.01 compared with the bare stent group.
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The PISCES Trial July 19, 2005:253–60espectively, when compared with the volume observed in
he bare stent group (D0). Although an ANOVA showed
n overall significant difference in SVs among the seven
roups, no significant difference in SV between group D5 or
6 and the bare stent (D0) could be specifically demon-
trated in an unpaired Student t test. The sequential analysis
f the proximal edge area of the bare stent showed a
ignificant reduction of the lumen due to constrictive
emodeling associated with an increase in plaque media.
here was a trend toward similar findings in group D1,
hereas no significant reduction in the lumen area of the
roximal or distal edge was observed in the other groups
D2 to D6). Significant increments in plaque area behind
he struts were observed in D2 to D6 as opposed to D0 and
1. The IVUS results are presented in Table 6.
ISCUSSION
his multi-center registry with the bare metal and
aclitaxel-eluting Conor stent is the first clinical application
f this novel stent technology. The results of this trial may
e summarized as follows: First, the bare stent, with
ntra-strut wells and relatively thick struts (127 m), yields
omparable acute and follow-up results and a safety profile
o that previously reported with conventional stainless steel
tents (9,10). Specifically, there was no undue incidence of
hrombotic episodes or unusual pattern of neointimal hy-
erplasia. Second, this novel eluting stent platform, with an
rodable polymer with complete elution of low doses of
aclitaxel, is safe. Third, the duration of release had greater
mpact on the inhibition of the in-stent neointimal hyper-
lasia than did dose. Despite application of approximately
0% to 30% of the dose of the commercially available
olymer-controlled paclitaxel-eluting stent, the inhibition
f neointimal hyperplasia was comparable. The principal
nding of this study is that, for paclitaxel, differing release
inetic profiles at similar doses seem to have profound
mpact on efficacy. Specifically, at the 10-g dose, the
10-day release formulations did not reduce the intra-stent
eointima observed in the bare metal stent group (31 mm3
s. 44 mm3, p  NS). In marked contrast, the 30-day
elease formulation of the same dose was highly efficacious
ith a 57% reduction in late loss and a 69% reduction in
ercent volume obstruction with IVUS when compared
ith the bare Conor stent. Furthermore, the 30-g/10-day
elease was less effective than one-third the dose released
ver a longer duration.
The precise reasons for these observations are unclear but
ay be related to several factors. First, molecular biology
tudies have demonstrated activation of genes potentially
esponsible for proliferation for periods up to 21 days (11).
s such, the inhibitory compound may need to be present
or some minimum period of time. Second, animal studies
ith the Conor drug delivery system have demonstrated
hat, at 30 days, all the doses used in the PISCES trial were
ffective, but slightly higher indexes of injury (e.g., fibrin reposition, eosinophilic deposits) were observed with the
horter release formulations (6). There were no significant
ifferences in the balloon-to-artery ratios between the dif-
erent groups, suggesting that the histologic variability was
harmacologic rather than mechanical. In these same stud-
es, at 90 days, there was durability of the 30-day results in
he longer release formulations that was not seen in the
horter release formulations. One may speculate that the
nti-proliferative effects of the drug may be blunted by a
econdary injury, induced either by the drug itself or by the
io-absorbable polymer, an effect which is not seen in the
onger releases. Our data may help explain some of the
iscordant data found in other paclitaxel clinical trials
3,4,12–14).
The TAXUS II study, a blinded, randomized trial with
wo paclitaxel treatment arms and two control arms, en-
olled over 500 patients. At drug concentrations of 1
g/mm2 (equivalent to a total drug loading of 108 g/
6-mm stent), delivered in either moderate or slow release
ormulations, restenosis rates of 5% and reductions in late
oss of 60% versus bare-metal control stent were reported.
lthough there were no reported toxic side-effects related to
he use of paclitaxel after 6 or 12 months, concern has been
aised about the long-term biological effect of the non-
rodable polymer used as well as persistence of significant
uantities of drug still present in the polymer at 30 days;
2.5% for the slow release formulation or 78.1% for the
oderate release (personal communication from Mary
ussell, June 2004).
The DELIVER trial also used paclitaxel—without a
olymer carrier—and failed, at a dose density of 3.04
g/mm2, to demonstrate significant improvement versus
he bare stent. The reasons for such discordant results with
he same drug are unclear, but suggest that release rates may
mpact efficacy (12). The present observation may therefore
ave relevance for optimizing paclitaxel efficacy and, poten-
ially, even have implications for other therapeutic com-
ounds.
A further finding of our study was that in dose 3, which
ad abluminal release only, and dose 2, which had bi-
irectional release, there was no differential efficacy either
n the in-stent segment or edges of the stent.
The IVUS observations made with the TAXUS polymer-
oated DES have been duplicated in these limited popula-
ions. First, a significant tissue growth behind the struts of
he stent has been observed, accompanied by expansive
emodeling of the external elastic membrane (15). Second,
umen reductions at the edge of the stent—predominantly
t the proximal edge—are usually seen after bare metal stent
mplantation, owing to constrictive remodeling combined
ith plaque growth. This phenomenon is prevented by the
aclitaxel-eluting stent, because the plaque growth is par-
ially accommodated by expansive remodeling (16).
tudy limitations. This study is subject to several limita-
ions. It was not designed as a pivotal efficacy study but
ather as a first-in-man study and, therefore, was not



















Stent length (mm) 19.0  6.6 18.3  4.2 18.8  5.2 17.7  2.8 18.0  2.2 17.9  2.7 17.0  1.0 0.63 0.57
Stent volume follow-up (mm3) 175  89 136  44† 150  73 141  32† 125  28‡ 146  34 144  30 0.01 0.32
Neointimal volume follow-up (mm3) 44  31 31  24 31  31 25  20‡ 16  21‡ 11  12‡ 8  10‡ 0.0001 0.0001
Obstruction volume follow-up % 26  13 22  13 20  17 17  13† 12  13‡ 8  7‡ 5  7‡ 0.0001 0.0001
Proximal (area mm2) n  28 n  21 n  15 n  20 n  16 n  22 n  17
Mean vessel post 17.4  4.2 15.5  5.0 14.6  4.7 17.1  3.6 15.3  4.4 15.9  4.5 15.5  3.7
Mean vessel follow-up 16.7  4.3 14.9  4.9 14.8  5.6 17.0  3.9 15.5  3.7 16.4  4.9 16.4  3.6
p value 0.03 0.34 0.83 0.95 0.68 0.15 0.2
Plaque post 7.9  2.8 7.5  2.7 7.0  3.3 7.7  2.9 6.8  2.5 7.2  2.5 7.1  2.8
Plaque follow-up 8.9  2.9 7.7  2.9 7.6  3.6 8.6  3.0 7.5  1.8 8.0  2.6 8.1  3.1
p value 0.004 0.75 0.09 0.08 0.11 0.0003 0.009
Mean lumen post 9.6  2.5 7.9  3.6 7.6  2.5 9.4  3.0 8.5  2.6 8.7  3.3 8.5  2.5
Mean lumen follow-up 7.8  2.9 7.2  2.9 7.2  3.2 8.5  3.2 8.0  3.1 8.4  3.6 8.3  2.7
p value 0.0001 0.047 0.45 0.08 0.23 0.39 0.77
Distal (area mm2) n  30 n  21 n  16 n  20 n  16 n  27 n  16
Mean vessel post 14.3  4.6 13.1  4.9 13.8  5.7 13.6  3.8 12.5  2.8 13.6  3.6 15.3  4.7
Mean vessel follow-up 14.6  4.8 13.1  4.3 13.6  4.9 13.6  3.6 13.3  2.5 13.9  3.3 15.6  4.3
p value 0.48 0.91 0.73 0.91 0.07 0.39 0.60
Plaque post 5.7  2.5 5.9  2.7 6.3  3.4 6.0  2.6 5.8  2.0 5.7  2.5 7.2  2.4
Plaque follow-up 6.6  2.7 6.6  2.9 7.0  4.0 6.3  2.6 6.5  1.8 6.4  2.3 7.9  2.5
p value 0.0001 0.09 0.08 0.19 0.04 0.003 0.01
Mean lumen post 8.6  3.3 7.2  2.7 7.5  3.5 7.6  2.6 6.7  2.2 7.9  2.3 8.2  2.8
Mean lumen follow-up 8.0  3.3 6.5  1.9 6.5  2.0 7.3  2.5 6.7  2.3 7.5  2.0 7.7  2.4
p value 0.13 0.09 0.19 0.48 0.88 0.12 0.22
PBS (area mm2) n  33 n  25 n  21 n  24 n  23 n  34 n  20
Post 9.6  3.0 7.8  2.8 7.8  2.4 8.6  2.1 7.7  2.1 7.7  2.0 8.2  1.7
Follow-up 9.5  2.5 8.2  2.6 8.6  2.6 9.3  2.4 8.7  2.1 9.1  2.2 9.3  1.8
p value 0.8 0.21 0.002 0.02 0.0004 0.0001 0.0001
*See Table 1 (release formulations): dose/duration/direction; †p 0.05 compared with the bare stent group; ‡p 0.01 compared with the bare stent group.
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The PISCES Trial July 19, 2005:253–60linded or randomized. As a pilot study, the primary
ollow-up was conducted at four months for safety reasons
imilar to other first-in-man studies. Comparison of the
eointimal hyperplasia at four months in the paclitaxel-
luting stent with the neointimal hyperplasia at six months
n the bare stent was not aimed to show superiority, but to
emonstrate that the novel platform itself was not providing
nusual results compared with conventional stainless steel
tents. Consequently, the study was not statistically modeled
o demonstrate efficacy but rather to develop insight into
ow to optimize the pharmacokinetics and to understand
he relative importance of different doses versus duration of
lution for paclitaxel.
onclusions. The PISCES trial demonstrates for the first
ime that kinetic variations play a key role in the efficacy of
ES systems. These findings may have significant implica-
ions for future research and development. Ongoing re-
earch activities with this reservoir-based technology involve
he ultra-thin cobalt-chromium stent in place of stainless
teel and long-release paclitaxel formulations. Evaluation of
ther compounds for indications other than restenosis is
lso underway. Future studies with respect to restenosis will
e larger and include longer-term follow-up, randomized
ohorts, and non-inferiority trials with other DES.
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